STOCK TITAN
  1. Home
  2. News
  3. PHXM

PHAXIAM THERAPEUTICS S A - PHXM STOCK NEWS

Welcome to our dedicated page for PHAXIAM THERAPEUTICS S A news (Ticker: PHXM), a resource for investors and traders seeking the latest updates and insights on PHAXIAM THERAPEUTICS S A stock.

PHAXIAM Therapeutics S A (PHXM) delivers innovative therapies for oncology and orphan diseases through its proprietary red blood cell encapsulation technology. This dedicated news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.

Access official press releases and verified updates about PHXM's pioneering research in tumor-related conditions and rare diseases. Our curated collection includes announcements about trial progress, manufacturing advancements from their Lyon facility, and collaborations enhancing therapeutic distribution.

Key updates cover drug encapsulation innovations, patient trial recruitment statuses, and European regulatory engagements. Bookmark this page for consolidated access to PHXM's latest scientific advancements and operational developments, presented with clarity for both expert analysts and engaged stakeholders.

News

Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024

Rhea-AI Summary
PHXM releases monthly information on total voting rights and share capital, showing stability in figures for February 2024. The company is listed on Euronext Paris and Nasdaq Global Select Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.4%
Tags
none
-
News

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

Rhea-AI Summary
PHAXIAM Therapeutics plans to voluntarily delist its American Depositary Shares from The Nasdaq Capital Market, focusing on Euronext Paris as its primary trading market. The delisting aims to reduce cash utilization and redirect resources towards key development milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.33%
Tags
none
-
News

Monthly information related to total number of voting rights and shares composing the share capital - January 31, 2024

Rhea-AI Summary
Pharnext, a biopharmaceutical company listed on Euronext Paris and Nasdaq, recently released a press release regarding the declaration of voting rights for the company's shares. The company's total shares and voting rights as of December 31, 2023, and January 31, 2024, were disclosed in accordance with the general regulation of French Autorité des Marchés Financiers. The press release provides the ISIN code and symbols for the company's shares on both Euronext and Nasdaq, along with the company's website. The release also explains the calculation of gross voting rights and net voting rights, including the treatment of shares with and without voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
News

PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

Rhea-AI Summary
PHAXIAM Therapeutics announces a cash position of €10.5 million as of December 31, 2023, enabling the company to fund its programs and expected operating expenses until July 2024. The company also plans to refinance in the first half of 2024. Additionally, the financial calendar for 2024 includes updates on business and key financial data for each quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Monthly information related to total number of voting rights and shares composing the share capital - December 31, 2023

Rhea-AI Summary
Pharnext (PHXM) Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - December 31, 2023. Pharnext, listed on Euronext Paris and Nasdaq Global Select Market, released monthly information related to the total number of voting rights and shares composing the share capital. The total of shares composing the share capital, total of brut and net voting rights, and the dates are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
News

Monthly information related to total number of voting rights and shares composing the share capital - November 30, 2023

Rhea-AI Summary
Monthly information related to total number of voting rights and shares composing the share capital for Phaxiam (PHXM) on Euronext Paris and Nasdaq Global Select Market. As of November 30, 2023, the total number of shares composing the share capital was 6,075,105 with 6,225,121 brut (1) voting rights and 6,225,872 net (2) voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
News

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Rhea-AI Summary
PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) provides a business and financial update for the third quarter of 2023, highlighting clinical development progress, financial figures, and upcoming milestones. The company aims to become a global phage therapy leader in high-value indications and has made significant advancements in its clinical and regulatory strategy, real-life activity data, and proprietary platform efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023

Rhea-AI Summary
Pharnext (PHXM) reports changes in voting rights, with a significant increase in the number of shares composing the share capital and voting rights in May and June 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.01%
Tags
none
-
News

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

Rhea-AI Summary
PHAXIAM Therapeutics receives approval for phase 1 study design in endocarditis infections caused by S. aureus
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
clinical trial
News

TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation

Rhea-AI Summary
PHAXIAM Therapeutics receives coverage initiation from TP ICAP Midcap with a 'Buy' recommendation and a valuation of €8.5 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.31%
Tags
none
Stock PHXM logo
PHAXIAM THERAPEUTICS S A

Nasdaq:PHXM

PHXM Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

PHXM Stock Data

19.86M
6.07M
2.69%
0.02%
Biotechnology
Healthcare
Link
France
Lyon